How cutaneous eruptions help to understand the mode of action of kinase inhibitors

British Journal of Dermatology

Volumn 167, Issue 5, 2012, Pages 965-967

  Dummer, R ^a   Tsao, H ^b   Robert, C ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

A RAF KINASE; B RAF KINASE; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; TREMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

CANCER GROWTH; CANCER REGRESSION; CELL GROWTH; CELL PROLIFERATION; DRUG MECHANISM; DRUG TARGETING; DRY SKIN; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HYPERKERATOSIS; JUVENILE MELANOMA; KERATOACANTHOMA; MELANOMA; ONCOGENE H RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PARONYCHIA; PRIORITY JOURNAL; RASH; SIGNAL TRANSDUCTION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

DRUG ERUPTIONS; HUMANS; INDOLES; MAP KINASE KINASE KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84868112185     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12080     Document Type: Editorial

References (22)

1. Zhang J, Yang PL, Gray NS,. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
2. Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008; 68: 664-73.
3. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.
4. Garnett MJ, Marais R,. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6: 313-19.
5. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-9.
6. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-901.
7. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
8. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
9. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
10. Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167: 987-94.
11. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-21.
12. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-15.
13. Ross AL, Sanchez MI, Grichnik JM,. Molecular nevogenesis. Dermatol Res Pract 2011; 2011: 463184.
14. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375-83.
15. Rinderknecht J, Goldinger S, Rozati S, et al. RASopathic skin eruptions during vemurafenib therapy. PLoS ONE 2012; (in press).
16. Schad K, Baumann Conzett K, Zipser MC, et al. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010; 16: 1058-64.
17. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-14.
18. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
19. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-76.
20. Kolev V, Mandinova A, Guinea-Viniegra J, et al. EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 2008; 10: 902-11.
21. Medzhitov R,. Origin and physiological roles of inflammation. Nature 2008; 454: 428-35.
22. Flaherty KT, Infante JR, Daud A, et al., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. J Engl J Med 2012; Sep 29 [Epub ahead of print]. PMID 23020132.